Radar · drug · signal

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaTrial safety note

Complete coverage checks before an early-window claim.

Statistical status

No screen yet

Receipt-date counts have not been screened.

Evidence score

—

Research priority weight, not a probability of causation or recovery.

Missing: none recorded

Competition

unknown

Observed in monitored channels only. Unknown is not zero.

Coverage unknown. Early-window label is blocked.

What changed

Qualitative review · trial
Stopped trial with safety-related language. Status SUSPENDED. Administrative hold pending non-safety related changes to the study design.
10/09/2026 · A termination is a lead only when the stated reason supports it.
Read the source

Receipt dates are the reporting screen. Event dates are a separate, lag-sensitive series. They are not added together.

Basis	Window	Covered days	Reports	Expected	Fold	Complete

Unknown. Court and RECAP collectors are not in this release. Do not read a blank docket as zero lawsuits.

No firm pages or ad notes. Competition stays unknown until the panel records one.